Protein-based nanoparticles as a drug delivery system: chances, risks, perspectives

被引:18
作者
Fuchs, S. [1 ]
Coester, C. [1 ]
机构
[1] Univ Munich, Dept Pharm Pharmaceut Technol & Biopharmaceut, D-81377 Munich, Germany
关键词
Drug delivery; Nanoparticles; Protein; Nanoparticle manufacturing; Targeting; PEGvlation; Biodistribution; Imaging; GLYCOL)-MODIFIED GELATIN NANOPARTICLES; FILLED ALBUMIN MICROSPHERES; SILK FIBROIN NANOPARTICLES; SMALL ANIMAL PET; IN-VIVO; CHITOSAN NANOPARTICLES; BREAST-CANCER; CPG OLIGONUCLEOTIDES; BOUND PACLITAXEL; IMMUNE-RESPONSE;
D O I
10.1016/S1773-2247(10)50056-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This review aims to provide a broad overview of the development of drug delivery nanoparticulate systems their classification by basic material preparation method and administration route while focusing on recent trends in the field of protein based nanoparticles Literature on drug delivery by nanotechnology was received in the light of previous and ongoing research Potentials and challenges including regulatory issues are discussed in the contest of possible applications of the miscellaneous nanoparticle devices Over the past years homogenous and clearly size defined nanoparticles have been successfully designed from a large variety of starting materials these nanoparticles offered diverse targeting or imaging properties in order to either enhance pharmacodynamic efficiency or reduce side effects of the delivered drug substance or to monitor the systems fate in vivo The latter is considered especially crucial when it comes to finally guiding nanoparticulate formulations through the clinical phase and its use for the patient's benefit in the end If the clinical requirements can be met the main promises of the new nanoparticulate formulations and associated new routes of drug delivery can be met (a) to enable new types of medicines to be carried to previously unaccessible sites within the body or (b) to reduce risks in delivering already established drugs
引用
收藏
页码:331 / 342
页数:12
相关论文
共 152 条
[1]   Nanoparticles for detection and diagnosis [J].
Agasti, Sarit S. ;
Rana, Subinoy ;
Park, Myoung-Hwan ;
Kim, Chae Kyu ;
You, Chang-Cheng ;
Rotello, Vincent M. .
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (03) :316-328
[2]   Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice [J].
Alignani, D ;
Maletto, B ;
Liscovsky, M ;
Rópolo, A ;
Morón, G ;
Pistoresi-Palencia, MC .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 77 (06) :898-905
[3]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[4]   Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system [J].
Amidi, M ;
Romeijn, SG ;
Borchard, G ;
Junginger, HE ;
Hennink, WE ;
Jiskoot, W .
JOURNAL OF CONTROLLED RELEASE, 2006, 111 (1-2) :107-116
[5]  
[Anonymous], 1992, APPL ORGANOMET CHEM
[6]  
ASPITIA AM, 2005, FUTURE ONCOL, V1, P755
[7]   Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes [J].
Balthasar, S ;
Michaelis, K ;
Dinauer, N ;
von Briesen, H ;
Kreuter, J ;
Langer, K .
BIOMATERIALS, 2005, 26 (15) :2723-2732
[8]  
Barbu E, 2009, EXPERT OPIN DRUG DEL, V6, P553, DOI [10.1517/17425240902939143 , 10.1517/17425240902939143]
[9]   CHARACTERISTICS OF ALBUNEX - AIR-FILLED ALBUMIN MICROSPHERES FOR ECHOCARDIOGRAPHY CONTRAST ENHANCEMENT [J].
BARNHART, J ;
LEVENE, H ;
VILLAPANDO, E ;
MANIQUIS, J ;
FERNANDEZ, J ;
RICE, S ;
JABLONSKI, E ;
GJOEN, T ;
TOLLESHAUG, H .
INVESTIGATIVE RADIOLOGY, 1990, 25 :S162-S164
[10]   STEALTH ME.PEG-PLA NANOPARTICLES AVOID UPTAKE BY THE MONONUCLEAR PHAGOCYTES SYSTEM [J].
BAZILE, D ;
PRUDHOMME, C ;
BASSOULLET, MT ;
MARLARD, M ;
SPENLEHAUER, G ;
VEILLARD, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :493-498